Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Accumulated Depreciation: 2019-2024

Historic Accumulated Depreciation for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $72.1 million.

  • Beam Therapeutics' Accumulated Depreciation rose 32.91% to $88.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.6 million, marking a year-over-year increase of 32.91%. This contributed to the annual value of $72.1 million for FY2024, which is 43.69% up from last year.
  • Latest data reveals that Beam Therapeutics reported Accumulated Depreciation of $72.1 million as of FY2024, which was up 43.69% from $50.2 million recorded in FY2023.
  • Over the past 5 years, Beam Therapeutics' Accumulated Depreciation peaked at $72.1 million during FY2024, and registered a low of $8.9 million during FY2020.
  • Its 3-year average for Accumulated Depreciation is $50.8 million, with a median of $50.2 million in 2023.
  • Data for Beam Therapeutics' Accumulated Depreciation shows a peak YoY spiked of 113.71% (in 2020) over the last 5 years.
  • Beam Therapeutics' Accumulated Depreciation (Yearly) stood at $8.9 million in 2020, then spiked by 80.71% to $16.1 million in 2021, then skyrocketed by 87.61% to $30.2 million in 2022, then surged by 66.33% to $50.2 million in 2023, then spiked by 43.69% to $72.1 million in 2024.